37 patents
Page 2 of 2
Utility
Prostate Specific Membrane Antigen Binding Protein
8 Apr 21
Disclosed are PSMA binding proteins with improved binding affinities, and robust aggregation profiles.
Robert DUBRIDGE, Pui SETO, Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
Filed: 23 Sep 20
Utility
PSMA Targeting Trispecific Proteins and Methods of Use
1 Apr 21
Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA.
Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
Filed: 16 Oct 20
Utility
Trispecific binding proteins and methods of use
23 Mar 21
Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen.
Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
Filed: 22 Jun 17
Utility
B cell maturation antigen binding proteins
23 Feb 21
Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA).
Holger Wesche, Bryan D. Lemon, Richard J. Austin
Filed: 12 Oct 18
Utility
DLL3 Binding Proteins and Methods of Use
18 Feb 21
Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein).
Holger WESCHE, Richard J. AUSTIN
Filed: 21 Aug 20
Utility
Prostate specific membrane antigen binding protein
30 Nov 20
Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles.
Robert Dubridge, Pui Seto, Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Bryan D. Lemon, Richard J. Austin
Filed: 21 Nov 17
Utility
PSMA targeting trispecific proteins and methods of use
23 Nov 20
Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA.
Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto
Filed: 21 Nov 17
Utility
DLL3 binding proteins and methods of use
26 Oct 20
Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein).
Holger Wesche, Richard J. Austin
Filed: 24 Sep 19
Utility
Mesothelin Binding Proteins
16 Sep 20
Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin.
Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
Filed: 26 Jan 20
Utility
MSLN Targeting Trispecific Proteins and Methods of Use
26 Aug 20
Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN.
Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
Filed: 25 Feb 20
Utility
MSLN targeting trispecific proteins and methods of use
3 Aug 20
Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN.
Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
Filed: 10 May 18
Utility
Single Chain Variable Fragment CD3 Binding Proteins
22 Jul 20
Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles.
Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
Filed: 26 Jan 20
Utility
Inducible Monovalent Antigen Binding Protein
13 May 20
Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage.
Patrick BAEUERLE, Holger WESCHE
Filed: 27 Feb 18
Utility
Compositions and Methods for Adoptive Cell Therapies
15 Apr 20
Provided herein are immune cells engineered to express one or more cell surface receptor polypeptides containing activatable antigen receptor polypeptides, and methods of use thereof for the treatment of diseases, including cancer.
Luke EVNIN, Holger WESCHE, Kevin WRIGHT
Filed: 2 May 18
Utility
DLL3 Binding Proteins and Methods of Use
25 Mar 20
Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein).
Holger WESCHE, Richard J. Austin
Filed: 24 Sep 19
Utility
Mesothelin binding proteins
27 Jan 20
Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin.
Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
Filed: 10 May 18
Utility
Single chain variable fragment CD3 binding proteins
27 Jan 20
Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles.
Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
Filed: 18 May 17